Our objective is to improve patients' quality of life by ensuring they have access to the
medications they require through our existing network of partners.
These drugs may stay unavailable in the nation where the patient is based until local
regulatory permission is received from the relevant local health authorities, and patient
access may be delayed as a result.
Fortunately, many health authorities throughout the Middle East Region permit expert
physicians to make formal requests on behalf of their patients, through their institutions
and health authorities, and in collaboration with pharmaceutical companies, in order to
obtain these critical unregistered medications.
We employ our best efforts to accommodate requests for such pharmaceuticals through
our Early Access Programs, in accordance with local laws and regulations, and in
consultation with physicians, institutions, appropriate authorities, and our business
partner
